Physician profile
Smita Bijlani
NPI 1578521118
$9,488.76
in general payments reported to CMS, 2019-2025
53 companies · $1,733 in 2025
The $1,733 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,342 · 2020: $596 · 2021: $1,026 · 2022: $1,739 · 2023: $1,709 · 2024: $1,344 · 2025: $1,733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,732 · Education: $54.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,731.87 |
| Education | $54.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,677.36 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $985.65 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Abbott Laboratories | $904.05 | 2019-2025 | Freestyle Libre 3 |
| Amgen INC. | $881.89 | 2019-2025 | Evenity, Tepezza, Prolia |
| Medtronic, INC. | $538.81 | 2021-2025 | Minimed 780g |
| Sanofi-Aventis U.S. LLC | $439.37 | 2019-2025 | |
| Horizon Therapeutics Plc | $395.04 | 2019-2023 | Tepezza |
| Ascendis Pharma Endocrinology INC | $256.01 | 2023-2025 | Yorvipath |
| Dexcom, INC. | $234.64 | 2019-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $231.47 | 2023-2025 | Korlym |
| Medtronic Minimed, INC. | $185.09 | 2019-2020 | |
| Radius Health, INC. | $181.92 | 2019-2025 | Tymlos |
| Abbvie INC. | $181.49 | 2019-2025 | Synthroid |
| Sequel Med Tech, LLC | $167.55 | 2025 | Twiist |
| Mannkind Corporation | $163.51 | 2019-2024 | Afrezza |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Smita Bijlani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.